title: GABA(B) modulation of dopamine release in the nucleus accumbens core.
abstract: Modulation of the concentration of dopamine (DA) released from dopaminergic terminals in the nucleus accumbens (NAc) influences behaviours such as the motivation to obtain drugs of abuse. γ-Aminobutyric acid type B (GABAB ) receptors are expressed throughout the mesolimbic circuit, including in the NAc, and baclofen, an agonist of GABAB receptors, can decrease drug-seeking behaviours. However, the mechanism by which GABAB receptors modulate terminal DA release has not been well studied. We explored how baclofen modulates the concentration of DA released from terminals in the NAc core using fast-scan cyclic voltammetry in brain slices from adult male C57BL/6J mice. We found that baclofen concentration-dependently decreased single pulse-evoked DA release. This effect was blocked by the GABAB antagonist, CGP 52432, but not by a nicotinic acetylcholine receptor antagonist. Suppression of DA release by a saturating concentration of baclofen was sustained for up to 1 h. The effect of baclofen was reduced with electrical stimulations mimicking burst firing of DA neurons. Similar to the D2 receptor agonist, quinpirole, baclofen reduced the probability of DA release, supporting a mechanistic overlap with D2 receptors. Baclofen-mediated suppression of DA release persisted after a locomotor-sensitizing cocaine treatment, indicating that GABAB receptors on DA terminals were not altered by cocaine exposure. These data suggest that baclofen-mediated suppression of terminal DA release is due to GABAB activation on DA terminals to reduce the probability of DA release. This effect does not readily desensitize, and persists regardless of chronic cocaine treatment.
authors.affiliation: Department of Anesthesiology, Pharmacology & Therapeutics, University of British Columbia, Vancouver, BC, Canada; Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada.
authors.forename: Kimberley A
authors.initials: KA
authors.lastname: Pitman
authors.forename: Ernest
authors.initials: E
authors.lastname: Puil
authors.forename: Stephanie L
authors.initials: SL
authors.lastname: Borgland
mesh_terms: D000818:Animals; D001418:Baclofen / Q000494:pharmacology*; D001596:Benzylamines / Q000494:pharmacology; D000697:Central Nervous System Stimulants / Q000494:pharmacology; D003042:Cocaine / Q000494:pharmacology; D004298:Dopamine / Q000378:metabolism*; D018491:Dopamine Agonists / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D058786:GABA-B Receptor Agonists / Q000494:pharmacology*; D058788:GABA-B Receptor Antagonists / Q000494:pharmacology; D008297:Male; D008810:Mice, Inbred C57BL; D009043:Motor Activity / Q000187:drug effects / Q000502:physiology; D009474:Neurons / Q000187:drug effects / Q000502:physiology; D018733:Nicotinic Antagonists / Q000494:pharmacology; D009714:Nucleus Accumbens / Q000187:drug effects* / Q000502:physiology*; D010721:Phosphinic Acids / Q000494:pharmacology; D019257:Quinpirole / Q000494:pharmacology; D017448:Receptors, Dopamine D2 / Q000819:agonists / Q000378:metabolism; D018080:Receptors, GABA-B / Q000378:metabolism*; D046509:Tissue Culture Techniques
chemical_list: D001596:Benzylamines; D000697:Central Nervous System Stimulants; D018491:Dopamine Agonists; D058786:GABA-B Receptor Agonists; D058788:GABA-B Receptor Antagonists; D018733:Nicotinic Antagonists; D010721:Phosphinic Acids; D017448:Receptors, Dopamine D2; D018080:Receptors, GABA-B; C083008:CGP 52432; D019257:Quinpirole; D001418:Baclofen; D003042:Cocaine; D004298:Dopamine
keywords: C57BL/6J mice; baclofen; cocaine; dopamine; voltammetry